Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deep-vein thrombosis

A W Lensing1, P Prandoni, M H Prins

  • 1Department of Vascular Medicine, Academic Medical Centre, Amsterdam, The Netherlands.

Lancet (London, England)
|February 16, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Longitudinal Study of Thrombosis and Bleeding Outcomes With Thromboprophylaxis in Pregnant Women at Intermediate and High Risk of VTE.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2023
Same author

Recommendations for the diagnosis and management of vaccine-induced immune thrombotic thrombocytopenia.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2021
Same author

Venous thromboembolism in cancer patients: a population-based cohort study.

Blood·2020
Same author

Thromboembolic and bleeding complications in patients with oesophageal cancer.

The British journal of surgery·2020
Same author

Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19].

Thrombosis research·2020
Same author

Perioperative bridging of anticoagulation: towards a more reserved approach.

The Netherlands journal of medicine·2019
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
Same journal

Indonesia's health reform: from pandemic mandate to the six pillars of transformation.

Lancet (London, England)·2026
Same journal

LGBTQ+ Russians increasingly avoiding doctors.

Lancet (London, England)·2026
See all related articles

Accurate diagnosis and treatment of symptomatic deep-vein thrombosis (DVT) are crucial for preventing recurrent venous thrombosis and pulmonary embolism. Objective tests confirm DVT in only 30% of symptomatic patients, guiding treatment duration based on risk factors.

Area of Science:

  • Vascular Medicine
  • Hematology
  • Diagnostic Imaging

Background:

  • Deep-vein thrombosis (DVT) is a significant complication of various disorders and can occur spontaneously.
  • Preventing recurrent venous thrombosis and pulmonary embolism necessitates accurate diagnosis and effective treatment.
  • This review focuses specifically on symptomatic deep-vein thrombosis.

Purpose of the Study:

  • To review the diagnostic challenges and treatment strategies for symptomatic deep-vein thrombosis.
  • To highlight the importance of objective testing in DVT diagnosis.
  • To discuss current approaches to anticoagulant therapy duration.

Main Methods:

  • Review of literature on deep-vein thrombosis diagnosis and management.
  • Analysis of diagnostic test accuracy (ultrasonography, D-dimer, clinical scoring).

Related Experiment Videos

  • Discussion of anticoagulant treatment protocols, including heparin and oral anticoagulants.

    • Main Results:

    • Objective tests confirm DVT in only approximately 30% of symptomatic patients.
    • Venous thromboembolic complications are infrequent (<1%) in untreated patients with rejected DVT based on diagnostic tests.
    • Initial heparin therapy should overlap with oral anticoagulants until the international normalised ratio (INR) is >2.0 for over 24 hours.

    Conclusions:

    • Accurate diagnosis of symptomatic DVT is challenging, with objective tests confirming the condition in a minority of cases.
    • Anticoagulant treatment initiation involves a transition from heparin to oral agents with specific INR monitoring.
    • The optimal duration of oral anticoagulant therapy remains undetermined and may depend on individual risk factors and recurrence history.